Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Fate Therapeutics Inc as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 188
- +7 vs. Q1 2023
- Shares held
- 109.1M
- −3.34M (−3.0%) vs. Q1 2023
- Total value
- $519.6M
- −$122.0M (−19.0%) vs. Q1 2023
- New holders
- 31
- 60 more added
- Sold out
- 24
- 58 more reduced
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FATE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 156 | $193.2M |
| Q1 2026 | 158 | $88.9M |
| Q4 2025 | 146 | $70.9M |
| Q3 2025 | 143 | $101.6M |
| Q2 2025 | 139 | $88.9M |
| Q1 2025 | 132 | $76.3M |
| Q4 2024 | 159 | $166.5M |
| Q3 2024 | 164 | $401.6M |
| Q2 2024 | 182 | $401.1M |
| Q1 2024 | 167 | $904.0M |
| Q4 2023 | 159 | $357.2M |
| Q3 2023 | 171 | $202.9M |
| Q2 2023 | 188 | $519.6M |
| Q1 2023 | 182 | $641.6M |
| Q4 2022 | 228 | $1.07B |
| Q3 2022 | 239 | $2.41B |
| Q2 2022 | 233 | $2.70B |
| Q1 2022 | 249 | $3.92B |
| Q4 2021 | 250 | $5.66B |
| Q3 2021 | 266 | $5.67B |
| Q2 2021 | 272 | $8.20B |
| Q1 2021 | 260 | $7.73B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Fate Therapeutics Inc; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Victory Capital Management Inc | 0 | $0 | 0.00% | −10,228−100.0% | Sold out |
| Advisors Asset Management, Inc. | 0 | $0 | 0.00% | −9,644−100.0% | Sold out |
| Ci Investments Inc. | 0 | $0 | 0.00% | −3,043−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −2,703−100.0% | Sold out |
| Riverview Trust Co | 0 | $0 | 0.00% | −2,497−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −1,407−100.0% | Sold out |
| Baillie Gifford & Co | 0 | $0 | 0.00% | −372−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −325−100.0% | Sold out |
| Itau Unibanco Holding S.A. | 0 | $0 | 0.00% | −226−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −185−100.0% | Sold out |
| Crewe Advisors LLC | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| ZRC Wealth Management, LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| ETF Managers Group, LLC | – | – | – | – | Not filed |